Search Results for “” – Page 10 – OSLM

OSLM

Outcome Studies
in Laboratory Medicine

guest

👤

Learn more about this platform

Categories:Model Economics

111 Publications found

Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.

b

Lung cancer (Amsterdam, Netherlands)

October 1, 2015

p Cancer

c Economics Model
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

b

Clinical lung cancer

September 1, 2015

p Cancer

c Economics Model
Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries.

b

The Journal of infectious diseases

August 15, 2015

p HIV POCT

c Economics Model
Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency.

b

Pediatrics

August 1, 2015

p Newborn Screening

c Economics Model
High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis.

b

Health technology assessment (Winchester, England)

June 1, 2015

p Cardiovascular Disease

c Economics Model
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.

b

Lung cancer (Amsterdam, Netherlands)

May 1, 2015

p Cancer

c Clinical outcomes Economics Model
Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.

b

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

April 1, 2015

p Cancer

c Economics Model
Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.

b

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

March 1, 2015

p Newborn Screening

c Economics Model
Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects.

b

Annals of the rheumatic diseases

February 1, 2015

p Therapeutic drug monitoring

c Economics Model
Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn’s disease patients who lose response to infliximab.

b

Journal of market access & health policy

January 1, 2015

p Therapeutic drug monitoring

c Economics Model